Drugs / PF-08634404
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07421700 | Mar 2026 → Dec 2027 expected | urothelial carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227415 | Feb 2026 → Nov 2027 expected | clear cell renal carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227298 | Jan 2026 → Mar 2029 expected | non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07227012 | Dec 2025 → Oct 2027 expected | hepatocellular carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07489066 | Jun 2026 → Jul 2028 expected | non-small cell squamous lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 2 | NCT07476287 | May 2026 → Mar 2028 expected | small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 2 | NCT06522828 | Oct 2024 → Aug 2025 overdue | reproductive system cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06493760 | Sep 2024 → Jun 2025 overdue | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06412471 | Jul 2024 → Jul 2025 | — | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06361927 | May 2024 → Jun 2025 | non-small cell lung carcinoma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07392892 | May 2026 → Jul 2031 expected | esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07226999 | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07578649 | Oct 2026 → Jun 2029 expected | endometrial cancer | Pfizer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07222566 | Jan 2026 → Feb 2029 expected | non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07222800 | Dec 2025 → Mar 2030 expected | colonic disorder, colorectal cancer, rectal disorder | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06980272 | Jun 2025 → Jul 2026 overdue | non-small cell lung carcinoma | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08634404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07227012 ↗ |
| Known as | SSGJ-707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980272 ↗ |
| Route | Intravenous | “Subjects receive SSGJ-707 intravenously.” NCT06980272 ↗ |